Urotensin II

Protocol	Assay Protocol (PDF)
Sample Preparation	Blood collection Plasma extraction Tissue extraction CSF extraction
Catalog #	EK-071-05
Standard Size	96 wells
Sensitivity	Minimum Detectable Concentration = 0.06 ng/ml
Range	0-100 ng/ml
Linear Range	0.06-1.48 ng/ml
Cross Reactivity	Peptide %Cross-reactivity   Urotensin II (Human)  100  Urotensin II(5-11) (Human)  22  Urotensin II (Rat)  18.2  Urotensin II Related Peptide (Human,Mouse, Rat)  15.7  Urotensin II (Mouse)  15.1  Urotentin II (4-11) (Human)  15  Urotensin II (102-125)-Prepro(Human)  0  Urotensin I (Catostomus commersoni)  0  Endothelin-1  0  Angiotensin II  0  ADM (Rat)  0  PAMP-20 (Human)  0  a-ANP-28 (Human)  0  CGRP (Rat)  0  CNP-22  0  BNP-25 (Rat)  0  BNP-32 (Rat)  0  Bradykinin  0  Neurotensin  0
Sequence	Glu - Thr - Pro - Asp - Cys - Phe - Trp - Lys - Tyr - Cys - Val Disulfide Bridge: Cys5 - Cys10
Standard Curve Image

Please click here or click the reference tab on the top to see more articles that use this product.

Links to publications that use this kit:

Tabur S, Korkmaz H, Eren MA, Oğuz E, Sabuncu T, Aksoy N. Urotensin-II level and its association with oxidative stress in early diabetic nephropathy.
J Diabetes Complicat. 2015;29(1):115-9.

Ulas T, Buyukhatipoglu H, Dal MS, et al. Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions.
J Res Med Sci. 2013;18(3):205-9. 

Hursitoglu M, Tukek T, Cikrikcioglu MA, et al. Urotensin II levels in patients with chronic kidney disease and kidney transplants.
Ups J Med Sci. 2012;117(1):22-7.

Babińska M, Holecki M, Prochaczek F, et al. Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome?.
Arch Med Sci. 2012;8(3):449-54.

Taylan A, Sari I, Kozaci DL, et al. Evaluation of various endothelial biomarkers in ankylosing spondylitis.
Clin Rheumatol. 2012;31(1):23-8.

Pehlivan Y, Onat AM, Comez G, Babacan T. Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.
Clin Rheumatol. 2011;30(6):837-42. 

Buyukhatipoglu H, Buyukaslan H, Pehlivan Y, et al. Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus.
Int J Rheum Dis. 2011;14(3):276-81.

Ozer O, Davutoglu V, Ercan S, et al. Plasma urotensin II as a marker for severity of rheumatic valve disease.
Tohoku J Exp Med. 2009;218(1):57-62.

Suguro et al. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.
Clin Sci (Lond). 2008 Dec;115(11):327-34.

Bicak et al. Possible pathogenic link between migraine and urotensin-II.
J Child Neurol. 2008 Nov;23(11):1249-53.

Zoccali et al. Urotensin II and cardiomyopathy in end-stage renal disease.
Hypertension. 2008 Feb;51(2):326-33.

Ravani et al. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease
Kidney Int. 2008 Jan;73(1):95-101.

Suguro et al. Increased Human Urotensin II Levels Are Correlated With Carotid Atherosclerosis in Essential Hypertension
Am J Hypertens. 2007 Feb;20(2):211-7.

Rdzanek et al. Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension.
Int J Cardiol. 2006 Jun 16;110(2):175-8.

Mallamaci et al. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease.
Am J Hypertens. 2006 May;19(5):505-10.

Watanabe et al. Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages
Hypertension. 2005 Oct;46(4):738-44.

Zoccali, C. et al. Kidney International. Vol. 00, 1-6 (2006); Mallamaci, F. et al. J Nephrol Vol. 18, 2005